HK1209637A1 - Pyrimido [4,5-b]quinoline-4,5 (3h,10h)-diones as nonsense mutation suppressors [45-b]-45(3h10h)- - Google Patents

Pyrimido [4,5-b]quinoline-4,5 (3h,10h)-diones as nonsense mutation suppressors [45-b]-45(3h10h)-

Info

Publication number
HK1209637A1
HK1209637A1 HK15110447.1A HK15110447A HK1209637A1 HK 1209637 A1 HK1209637 A1 HK 1209637A1 HK 15110447 A HK15110447 A HK 15110447A HK 1209637 A1 HK1209637 A1 HK 1209637A1
Authority
HK
Hong Kong
Prior art keywords
pyrimido
diones
quinoline
nonsense mutation
mutation suppressors
Prior art date
Application number
HK15110447.1A
Other languages
English (en)
Chinese (zh)
Inventor
Edgar Jacoby
Juergen Reinhardt
Niko Schmiedeberg
Carsten Spanka
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50030361&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HK1209637(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of HK1209637A1 publication Critical patent/HK1209637A1/xx

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Inorganic Chemistry (AREA)
  • Plural Heterocyclic Compounds (AREA)
HK15110447.1A 2012-12-13 2015-10-23 Pyrimido [4,5-b]quinoline-4,5 (3h,10h)-diones as nonsense mutation suppressors [45-b]-45(3h10h)- HK1209637A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261736748P 2012-12-13 2012-12-13
PCT/IB2013/060859 WO2014091446A1 (fr) 2012-12-13 2013-12-12 Pyrimido [4,5-b]quinoline-4,5 (3h,10h)-diones utilisés en tant que suppresseurs de mutation non-sens

Publications (1)

Publication Number Publication Date
HK1209637A1 true HK1209637A1 (en) 2016-04-08

Family

ID=50030361

Family Applications (1)

Application Number Title Priority Date Filing Date
HK15110447.1A HK1209637A1 (en) 2012-12-13 2015-10-23 Pyrimido [4,5-b]quinoline-4,5 (3h,10h)-diones as nonsense mutation suppressors [45-b]-45(3h10h)-

Country Status (24)

Country Link
US (2) US9649314B2 (fr)
EP (1) EP2931282B1 (fr)
JP (1) JP6076498B2 (fr)
KR (1) KR101760586B1 (fr)
CN (2) CN104837490B (fr)
AP (1) AP2015008441A0 (fr)
AU (1) AU2013358591B2 (fr)
BR (1) BR112015013535A2 (fr)
CA (1) CA2890692A1 (fr)
CL (1) CL2015001610A1 (fr)
CR (1) CR20150314A (fr)
CU (1) CU20150061A7 (fr)
EA (1) EA028673B1 (fr)
ES (1) ES2709034T3 (fr)
HK (1) HK1209637A1 (fr)
IL (1) IL239244A0 (fr)
IN (1) IN2015DN03998A (fr)
MA (1) MA38157A1 (fr)
MX (1) MX363437B (fr)
PE (1) PE20151062A1 (fr)
PH (1) PH12015501216A1 (fr)
SG (1) SG11201503684WA (fr)
TN (1) TN2015000262A1 (fr)
WO (1) WO2014091446A1 (fr)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2013358591B2 (en) 2012-12-13 2016-08-25 Novartis Ag Pyrimido [4,5-b]quinoline-4,5 (3H,10H)-diones as nonsense mutation suppressors
WO2015186061A1 (fr) * 2014-06-03 2015-12-10 Novartis Ag Dérivés de pyridopyrimidinedione
JP6560257B2 (ja) * 2014-06-03 2019-08-14 ノバルティス アーゲー ピリミド[4,5−b]キノリン−4,5(3H,10H)−ジオン誘導体
TN2016000490A1 (en) * 2014-06-03 2018-04-04 Novartis Ag Naphthyridinedione derivatives.
CN109152747A (zh) * 2016-04-15 2019-01-04 Uab研究基金会 用于刺激提前终止密码子的通读的方法和化合物
WO2019173437A1 (fr) * 2018-03-06 2019-09-12 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Modulateurs allostériques positifs du récepteur de la dopamine 1 et procédé d'utilisation associé
WO2019225625A1 (fr) * 2018-05-23 2019-11-28 京都薬品工業株式会社 Inducteur de translecture et utilisation pharmaceutique associée
EP4211171A2 (fr) 2020-09-10 2023-07-19 Precirix N.V. Fragment d'anticorps contre fap
MX2023008296A (es) 2021-01-13 2023-09-29 Monte Rosa Therapeutics Inc Compuestos de isoindolinona.
WO2023203135A1 (fr) 2022-04-22 2023-10-26 Precirix N.V. Anticorps radiomarqué amélioré
WO2023213801A1 (fr) 2022-05-02 2023-11-09 Precirix N.V. Pré-ciblage

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2884170B2 (ja) 1989-08-24 1999-04-19 株式会社フジモト・ブラザーズ 5−デアザフラビン系化合物を有効成分とする制癌剤
US5908930A (en) 1995-03-15 1999-06-01 Pfizer Inc. 5,10-dihydropyrimdo 4,5-b!quinolin-4(1H)-one tyrosine kinase inhibitors
US6468990B1 (en) 1999-05-17 2002-10-22 Queen's University At Kingston Method of inhibiting binding of nerve growth factor to p75 NTR receptor
WO2004078163A2 (fr) 2003-02-28 2004-09-16 Transform Pharmaceuticals, Inc. Compositions pharmaceutiques a base d'un co-cristal
WO2004006906A2 (fr) 2002-07-15 2004-01-22 Combinatorx, Incorporated Methodes de traitement de neoplasmes
HUE031794T2 (en) 2003-04-11 2017-08-28 Ptc Therapeutics Inc 1,2,4-oxadiol-benzoic acid compounds and their use for nonsense suppression and disease treatment
ES2594343T3 (es) 2006-04-03 2016-12-19 Technion Research & Development Foundation Limited Aminoglucósidos novedosos y usos de los mismos en el tratamiento de trastornos genéticos
AU2007288198A1 (en) 2006-08-23 2008-02-28 Neurogen Corporation Haloalkyl-substituted pyrimidinone derivatives
WO2009086303A2 (fr) 2007-12-21 2009-07-09 University Of Rochester Procédé permettant de modifier la durée de vie d'organismes eucaryotes
EP2422817A1 (fr) 2010-07-29 2012-02-29 INSERM (Institut National de la Santé et de la Recherche Médicale) Conjugués flavine-ligand d'acide nucléique
EP2600865B1 (fr) 2010-08-05 2018-11-14 Université de Lille Composé utile pour le traitement de maladies médiées par une mutation non-sens et composition pharmaceutique comprenant ledit composé
AU2013358591B2 (en) 2012-12-13 2016-08-25 Novartis Ag Pyrimido [4,5-b]quinoline-4,5 (3H,10H)-diones as nonsense mutation suppressors

Also Published As

Publication number Publication date
KR20150092306A (ko) 2015-08-12
US20150335646A1 (en) 2015-11-26
AP2015008441A0 (en) 2015-05-31
WO2014091446A1 (fr) 2014-06-19
IL239244A0 (en) 2015-07-30
CL2015001610A1 (es) 2015-08-07
CN104837490B (zh) 2017-10-03
IN2015DN03998A (fr) 2015-10-02
SG11201503684WA (en) 2015-06-29
CN107569487A (zh) 2018-01-12
EP2931282A1 (fr) 2015-10-21
EA201591105A1 (ru) 2015-10-30
ES2709034T3 (es) 2019-04-12
MA38157A1 (fr) 2016-12-30
AU2013358591B2 (en) 2016-08-25
MX2015007562A (es) 2015-10-14
JP6076498B2 (ja) 2017-02-08
AU2013358591A1 (en) 2015-05-28
PH12015501216A1 (en) 2015-08-17
TN2015000262A1 (en) 2016-10-03
PE20151062A1 (es) 2015-08-05
EP2931282B1 (fr) 2018-10-31
MX363437B (es) 2019-03-22
CR20150314A (es) 2015-08-10
CU20150061A7 (es) 2015-12-23
KR101760586B1 (ko) 2017-07-21
BR112015013535A2 (pt) 2017-07-11
CA2890692A1 (fr) 2014-06-19
CN104837490A (zh) 2015-08-12
JP2016503003A (ja) 2016-02-01
EA028673B1 (ru) 2017-12-29
US9649314B2 (en) 2017-05-16
US20170266189A1 (en) 2017-09-21

Similar Documents

Publication Publication Date Title
HK1209637A1 (en) Pyrimido [4,5-b]quinoline-4,5 (3h,10h)-diones as nonsense mutation suppressors [45-b]-45(3h10h)-
HRP20181349T1 (hr) Derivat tetrahidroimidazo[1,5-d][1,4]oksazepina
HK1246792A1 (zh) 6,7-二氫吡唑並[1,5-a]吡嗪-4(5h)-酮化合物
IL254224A0 (en) 7-substituted 5-alkyl-[4,2,1]triazolo[5,1-a]pyrimidine derivatives as pde2 inhibitors
HK1219277A1 (zh) 新的三唑並 嘧啶衍生物
ZA201408843B (en) Imidazo[1,2-b]pyridazine derivative as kinase inhibitor
HK1210167A1 (en) Macrocycle picolinamides as fungicides -2-
IL234485A (en) Compounds based on imidazo [2,1 – b] pyridazine
HK1199879A1 (en) Pde9 inhibitors with imidazo triazinone backbone pde9
SI2812337T1 (sl) Furo (3,2-b) in tieno (3,2-b) piridinski derivati kot zaviralci tbk1 in ikk
EP2938344A4 (fr) Composés [1,2,4]triazolo[1,5-c]quinazolin-5-amines à substitution par pipérazine ayant des propriétés d'antagonistes du récepteur a2a
PT3129374T (pt) (5,6-dihidro)pirimido[4,5-e] indolizinas
HK1187614A1 (zh) 咪唑並吡嗪
EP2808108A4 (fr) Tour d'usinage complexe
HK1206354A1 (en) Pyrrolo[2,3-b]pyrazines as syk inhibitors syk [23-b]
ZA201507151B (en) Antiviral indolo[2,3-b]quinoxaline
HK1209419A1 (en) Solid form of dihydro pyrido oxazine derivative
IL236808B (en) Piperazino[1,2-a]indol-1-ones and [1,4]diazepino[1,2-a]indol-1-one
GB201221462D0 (en) Novel isothiazolo[5,4-b]pyridines
GB201219129D0 (en) Triazolo(4,5-d)pyrmindine compounds
AU344103S (en) Modular outdoor seating
GB201211756D0 (en) Novel isothiazolo [4,3-b]pyridines